Gangolli Julian S — SEC Form 4 filings
SEC reporting owner CIK 1532023. 9 Form 4 filings on record with FilingPulse; latest filed 2026-09-16.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-03-08 to 2026-09-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 20,000 shares, $3,282,690 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 10,930 shares @ $163.71 ($1,789,310) in Krystal Biotech, Inc., filed 2024-05-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | Director | 4 | — | 3 legs · 20,000 sh · $3,282,690 | 6 |
| Outlook Therapeutics, Inc. (OTLK) | Director | 3 | — | — | 4 |
| Revance Therapeutics, Inc. (RVNC) | Director | 2 | — | — | 4 |
Form 4 filings — Gangolli Julian S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | Krystal Biotech, Inc. (KRYS) | Grant/award (A): 1,187 (derivative) @ $0 · Grant/award (A): 471 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Outlook Therapeutics, Inc. (OTLK) | Grant/award (A): 286,734 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Krystal Biotech, Inc. (KRYS) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Code (U): 30,106 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2024-10-03 | 4 | Outlook Therapeutics, Inc. (OTLK) | Grant/award (A): 56,636 (derivative) @ $0 · Grant/award (A): 71,169 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Krystal Biotech, Inc. (KRYS) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Krystal Biotech, Inc. (KRYS) | Option exercise (M): 20,000 @ $22.75 · Sale (S): 10,930 @ $163.71 · Sale (S): 7,090 @ $164.34 · Sale (S): 1,980 @ $165.76 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | Outlook Therapeutics, Inc. (OTLK) | Grant/award (A): 94,441 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1532023 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →